The FDA’s approval for expanded use reinforces LP-310’s potential as a new therapeutic option for OLP and supports ongoing clinical development efforts.
Ruling found patent doesn’t claim drug’s key complex, MSN says Move is latest in flurry of district, appeals court filings A Novartis AG patent for Entresto revived this month doesn’t cover the ...
The FDA also gave its nod to Bristol Myers Squibb’s Cobenfy (xanomeline and trospium chloride), the first new class of antischizophrenia drug to be approved in decades. Roughly one-third of last ...
With respiratory-disease season in full swing and a bird flu outbreak rapidly evolving, the new Trump Administration has ordered federal health agencies to secure White House approval before ...